PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic to present additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, reinforcing potential in Progressive Multiple Sclerosis. Latest research findings to be shared at event -
-
-
PRESS RELEASE
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic Inc. highlights its 2025 accomplishments & upcoming milestones including phase 3 trials for Vidofludimus Calcium in relapsing Multiple Sclerosis, positive data in Progressive MS, & potential for IMU-856 in weight management -
-
-
PRESS RELEASE
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic to participate in the 8th Annual Evercore ISI Healthcare Conference in December. Dr. Daniel Vitt to speak at fireside chat on novel oral therapies for neurologic and gastrointestinal diseases
